Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
— Presentation entitled “BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility” – — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — Vancouver, British Columbia, April 10, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel…
